Page 184 - 2018_11-Haematologica-web

P.A. Carpenter et al.
9. Couriel DR, Saliba R, Escalon MP, et al.
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130(3):409-417.
10. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074-3080.
11. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108 (2):756-762
12. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host dis- ease. Biol Blood Marrow Transplant. 2005;11(4):307-313.
13. Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-ver- sus-host disease. J Clin Oncol. 2007;25(27): 4255-4261.
14. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent inter- leukin-2 production. Blood. 2006;108(1): 390-399.
15. Zeiser R, Leverson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-462.
16. Coenen JJ, Koenen HJ, van Rijsen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preserva- tion of CD4+Cd25+FoxP3+ T cells. Bone Marrow Transplant. 2007;39(9):537-545.
17. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood.
2008;112(4):1515-1521.
18. Biagi E, Di Biaso I, Leoni V, et al.
Extracorporeal photochemotherapy is accompanied by increasing levels of circulat- ing CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84(1):31-39.
19. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
20. Pavletic SZ, Martin PJ, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response crite- ria working group report. Biol Blood Marrow Transplant. 2006;12(3):252-266.
21. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report. Biol Blood Marrow Transplant. 2006;12(5):491-505.
22. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant. 2015;21(7):1167-1187.
23. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(6):3865-3874.
24. Ware JE, Kosinski M, Bjorner JB, et al. User's Manual for the SF-36v2 Health Survey. 2nd edn. QualityMetric Incorporated; Lincoln, RI: 2007.
25. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(1):47-55.
26. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129 (1):30-37.
27. Duarte RF, Greinix H, Rabin B, et al. Uptake and use of recommendations for the diagno- sis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplant. 2014;49(1):49-54.
28. https://clinicaltrials.gov/ct2/show/ NCT01879072
29. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.
30. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus- host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria work- ing group report. Biol Blood Marrow Transplant. 2015;21(6):984-99.
31. Inamoto Y, Flowers ME, Sandmaier BM, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host dis- ease. Blood. 2014;124(8):1363-1371.
32. Palmer J, Chai X, Martin PJ, et al. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica. 2015;100(5):690-695.
33. Martin PJ, Storer BE, Inamoto Y, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-ver- sus-host disease. Blood. 2017;130(3):360- 367.
1924
haematologica | 2018; 103(11)